An Efficient Synthesis of 6-Nitro-
and 6-Amino-3H-imidazo[4,5-b]pyridines by Cyclocondensation
of 1-Substituted 1H-Imidazol-5-amines
with 3-Nitro-4H-chromen-4-one

Dmytro Ostrovskyi; Viktor O. Iaroshenko; Andranik Petrosyan; Sergii Dudkin; Iftikhar Ali; Alexander Villinger; Andrei Tolmachev; Peter Langer

doi:10.1055/s-0030-1258538

LETTER

An Efficient Synthesis of 6-Nitro- and 6-Amino-3H-imidazo[4,5-b]pyridines by Cyclocondensation of 1-Substituted 1H-Imidazol-5-amines with 3-Nitro-4H-chromen-4-one

Dmytro Ostrovskyi^a, Viktor O. Iaroshenko*^a,b, Andranik Petrosyan^a, Sergii Dudkin^a, Iftikhar Ali^a, Alexander Villinger^a, Andrei Tolmachev^b,c, Peter Langer*^a,d
^a Institut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany
Fax: +49(381)4986412; e-Mail: viktor.iaroshenko@uni-rostock.de; e-Mail: iva108@googlemail.com; e-Mail: peter.langer@uni-rostock.de;
^b National Taras Shevchenko University, 62 Volodymyrska st., 01033 Kyiv-33, Ukraine
^c ‘Enamine Ltd.’, 23 A. Matrosova st., 01103 Kyiv, Ukraine
^d Leibniz-Institut für Katalyse an der Universität Rostock e.V., Albert Einstein Str. 29a, 18059 Rostock, Germany

Abstract

All articles of this category

Abstract

The reaction of 3-nitro-4H-chromen-4-one with in situ generated 1-substituted 5-amino-1H-imidazoles affords a set of 1-substituted 6-nitro-3H-imidazo[4,5-b]pyridines which represent potential adenosine deaminase (ADA) inhibitors. Reduction of the nitro group results in the formation of the corresponding 6-amino-3H-imidazo[4,5-b]pyridines.

Key words

cyclization - chromones - N-heterocycles - imidazoles - purine isosteres

Full Text

References

References and Notes

<A NAME="RG12910ST-1A">1a</A> Dubey PK. Kumar RV. Naidu A. Kulkarni SMA. Asian J. Chem. 2002, 14: 1129

<A NAME="RG12910ST-1B">1b</A> Lee SCh. Choi JS. Oh JH. Park B. Kim YE. Lee JH. Shin D. Kim ChM. Hyun Y.-L. Lee ChS. Cho J.-M. Ro S. WO 2007083978, 2007, Chem. Abstr. 2007, 147: 817587

<A NAME="RG12910ST-1C">1c</A> Kelly MG, Kincaid J, Duncton M, Sahasrabudhe K, Janagani S, Upasani RB, Wu G, Fang Y, and Wei Zh.-L. inventors; US 2006194801. ; Chem. Abstr. 2006, 145, 889269

<A NAME="RG12910ST-1D">1d</A> Randolph JT, Chen H, Degoey DA, Flentge ChA, Flosi WJ, Grampovnik DJ, Huang PP, Hutchinson DK, Kempf DJ, Klein LL, and Yeung MC. inventors; US 2005159469. ; Chem. Abstr. 2005, 143, 641882

<A NAME="RG12910ST-1E">1e</A> Kivlighn SD. Zingaro GJ. Gabel RA. Broten TP. Schorn TW. Schaffer LW. Naylor EM. Chakravarty PK. Patchett AA. Greenlee WJ. Siegl PKS. Am. J. Hypertens. 1995, 8: 58

<A NAME="RG12910ST-2A">2a</A> Pagani ED. Dundore RL. Bode DC. Bacon ER. Singh B. Lesher GY. Buchholz RA. Silver PJ.
J. Cardiovasc. Pharmacol. 1994, 24: 403

<A NAME="RG12910ST-2B">2b</A> Joseph EC. Rees JA. Dayan A. Toxicol. Pathol. 1996, 24: 436

<A NAME="RG12910ST-2C">2c</A> Garvey DS, Saenz de Tejada I, Earl RA, and Khanapure SP. inventors; US 6331543. ; Chem. Abstr. 2001, 136, 916407

<A NAME="RG12910ST-3A">3a</A> Ida K, Otsubo N, Kuboyama T, Arai H, Watanabe A, Saki M, Hiura N, Manabe H, Takada H, and Saito J. inventors; WO 2005082905. ; Chem. Abstr. 2005, 143, 979654

<A NAME="RG12910ST-3B">3b</A> Magnuson S, Dixon J, Phillips B, Khire U, Wang L, Zhang Zh, Patel M, Kumarasinghe ES, Wickens P, and Olague A. inventors; WO 2007064932. ; Chem. Abstr. 2007, 147, 618350

<A NAME="RG12910ST-3C">3c</A> Bavetsias V. Sun C. Bouloc N. Reynisson J. Workman P. Linardopoulos S. McDonald E. Bioorg. Med. Chem. Lett. 2007, 17: 6567

<A NAME="RG12910ST-4">4</A> Zielke CI. Suelter CH. Purine, Purine Nucleoside, and Purine Nucleotide Aminohydrolases, In The Enzymes Vol. 4: Boyer PD. Academic Press; New York: 1971. p.47

<A NAME="RG12910ST-5A">5a</A> Cristalli G. Costanzi S. Lambertucci C. Lupidi G. Vittori S. Volpini R. Camaioni E. Med. Res. Rev. 2001, 21: 105

<A NAME="RG12910ST-5B">5b</A> Maydanovych O. Beal PA. Chem. Rev. 2006, 106: 3397

<A NAME="RG12910ST-5C">5c</A> Nair V. IMPDH Inhibitors: Discovery of Antiviral Agents Against Emerging Diseases, In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats Torrence PF. John Wiley and Sons; Hoboken: 2005. Chap. 8. p.179-202

<A NAME="RG12910ST-5D">5d</A> Shu Q. Nair V. Med. Res. Rev. 2008, 219

<A NAME="RG12910ST-6A">6a</A> Agarwal RP. Pharmac. Ther. 1982, 17: 399

<A NAME="RG12910ST-6B">6b</A> Weber G. Cancer Res. 1983, 43: 3466

<A NAME="RG12910ST-7">7</A> Pankiewicz KW. Goldstein BM. Inosine Mono Phosphate Dehydrogenase, ACS Symposium Series 839 American Chemical Society; Washington DC: 2003.

<A NAME="RG12910ST-8A">8a</A> Burns CM. Chu H. Rueter SM. Hutchinson LK. Canton H. Sanders-Bush E. Emeson RB. Nature (London) 1997, 387: 303

<A NAME="RG12910ST-8B">8b</A> Higuchi M. Single FN. Kohler M. Sommer B. Sprengel R. Seeburg PH. Cell 1993, 75: 1361

<A NAME="RG12910ST-9A">9a</A> Giblett ER. Anderson JE. Cohen F. Pollara B. Meuwissen HJ. Lancet 1972, 2: 1067

<A NAME="RG12910ST-9B">9b</A> Hirshhorn R. Clin. Immunol. Immunophathol. 1995, 76: 219

<A NAME="RG12910ST-10A">10a</A> Niedzwicki JG. Kouttab NM. Mayer KH. Carpenter CC. Parks RE. Abushanab E. Abernethy DR. J. Acquir. Immune Defic. Syndr. 1991, 4: 178

<A NAME="RG12910ST-10B">10b</A> Salvatore D. Claudio MM. Anna PM. Clin. Chem. 1987, 33: 1675

<A NAME="RG12910ST-10C">10c</A> Valenzuela A. Blanco J. Callebaut C. Jacotot E. Lluis C. Hovanessian AG. Franco R.
J. Immunol. 1997, 158: 3721

<A NAME="RG12910ST-11A">11a</A> Ungerer JPJ. Oosthuizen HM. Retief JH. Bissbort SH. Chest 1994, 106: 33

<A NAME="RG12910ST-11B">11b</A> Banales JL. Rivera Martinez E. Perez Gonzalez L. Selman M. Raymond Y. Nava A. Arch. Med. Res. 1999, 30: 358

<A NAME="RG12910ST-12A">12a</A> Chiba S. Matsumoto H. Saitoh M. Kasahara M. Matsuya M. Kashiwagi MA. J. Neurol. Sci. 1995, 132: 170

<A NAME="RG12910ST-12B">12b</A> Gakis C. Eur. Respir. J. 1996, 9: 632

<A NAME="RG12910ST-13A">13a</A> Demeocq F. Viallard JL. Boumsell L. Richard Y. Chassgne J. Plagne R. Lemerle J. Bernard A. Leuk. Res. 1982, 6: 211

<A NAME="RG12910ST-13B">13b</A> Carlucci F. Rosi F. Di Pietro C. Marinello E. Biochim. Biophys. Acta 1997, 1360: 203

<A NAME="RG12910ST-14">14</A> Silverman RB. The Organic Chemistry of Drug Design and Drug Action 2nd ed.: Elsevier Academic Press; New York: 2004. p.617 ; ISBN 0-12-643732-7

<A NAME="RG12910ST-15">15</A> Agarwal RP. Spector T. Parks RE. Biochem. Pharmacol. 1977, 26: 359

<A NAME="RG12910ST-16A">16a</A> Frick L. Yang C. Marquez VE. Wolfenden R. Biochemistry 1989, 28: 9423

<A NAME="RG12910ST-16B">16b</A> Ashley GW. Bartlett PA. J. Biol. Chem. 1984, 259: 13621

<A NAME="RG12910ST-17A">17a</A> Shewach DS. Krawczyk SH. Acevedo OL. Townsend LB. Biochem. Pharmacol. 1992, 44: 1697

<A NAME="RG12910ST-17B">17b</A> Frieden C. Kurz LC. Gilbert HR. Biochemistry 1980, 19: 5303

<A NAME="RG12910ST-18A">18a</A> Wang Z. Quiocho FA. Biochemistry 1998, 37: 8314

<A NAME="RG12910ST-18B">18b</A> Wilson DK. Rudolph FN. Quiocho FA. Science 1991, 252: 1278

<A NAME="RG12910ST-18C">18c</A> Kinoshita T. Nishio N. Nakanishi I. Sato A. Fujii T. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2003, 59: 299

<A NAME="RG12910ST-19A">19a</A> Illuminati G. Stegel F. Tetrahedron Lett. 1968, 39: 4169

<A NAME="RG12910ST-19B">19b</A> Terrier F. Chatrousse A.-P. Schaal R. J. Org. Chem. 1972, 37: 3010

<A NAME="RG12910ST-19C">19c</A> Biffin MEC. Miller J. Moritz AG. Paul D. Aust. J. Chem. 1970, 23: 957

<A NAME="RG12910ST-19D">19d</A> Terrier F. Sebban M. Goumont R. Halle JC. Moutiers G. Cangelosi I. Buncel E. J. Org. Chem. 2000, 65: 7391

<A NAME="RG12910ST-20">20</A> Seeliger F. Blazej S. Bernhardt S. Makosza M. Mayr H. Chem. Eur. J. 2008, 14: 6108

<A NAME="RG12910ST-21A">21a</A> Iaroshenko VO. Sevenard DV. Kotljarov AV. Volochnyuk DM. Tolmachev AO. Sosnovskikh VYa. Synthesis 2009, 731

<A NAME="RG12910ST-21B">21b</A> Iaroshenko VO. Wang Y. Sevenard DV. Volochnyuk DM. Synthesis 2009, 1851

<A NAME="RG12910ST-21C">21c</A> Iaroshenko VO. Sevenard DV. Volochnyuk DM. Wang Y. Martiloga A. Tolmachev AO. Synthesis 2009, 1865

<A NAME="RG12910ST-21D">21d</A> Iaroshenko VO. Wang Y. Zhang B. Volochnyuk DM. Sosnovskikh VYa. Synthesis 2009, 2393

<A NAME="RG12910ST-21E">21e</A> Kotljarov A. Irgashev RA. Iaroshenko VO. Sevenard DV. Sosnovskikh VYa. Synthesis 2009, 3233

<A NAME="RG12910ST-21F">21f</A> Kotljarov A. Iaroshenko VO. Volochnyuk DM. Irgashev RA. Sosnovskikh VYa. Synthesis 2009, 3869

<A NAME="RG12910ST-21G">21g</A> Iaroshenko VO. Synthesis 2009, 3967

<A NAME="RG12910ST-22A">22a</A> Perrella FW. Chen S.-F. Behrens DL. Kaltenbach RF. Seitz SP. J. Med. Chem. 1994, 37: 2232

<A NAME="RG12910ST-22B">22b</A> Becket GJP. Ellis GP. Tetrahedron Lett. 1976, 9: 719

<A NAME="RG12910ST-23A">23a</A> Takagi K. Tanaka M. Murakami Y. Ogura K. Ishii K. Morita H. Aotsuka T. J. Heterocycl. Chem. 1987, 24: 1003

<A NAME="RG12910ST-23B">23b</A> Connor DT. Young PA. von Strandtmann M. J. Heterocycl. Chem. 1981, 18: 697

<A NAME="RG12910ST-23C">23c</A> Haas G. Stanton JL. Winkler T. J. Heterocycl. Chem. 1981, 18: 619

<A NAME="RG12910ST-24">24</A> Wesch T. Iaroshenko VO. Groth U. Synlett 2008, 1459

General Procedure for the Synthesis of Compounds 6a-q
To a Schlenk flask, set with reflux, CH₂Cl₂ (2.5 mL), primary amine (0.00131 mol), and methyl N-(cyanomethyl)-formimidate (1, 0.128 g, 0.00131 mol) were added under an argon atmosphere at r.t. The reaction mixture was refluxed during 2 h and after that, the mixture was cooled down to r.t., and then to 0 ˚C on an ice bath. Afterwards 3-nitro-4H-chromen-4-one (0.25 g, 0.00131 mol) was added, and the mixture continued to stir at the same temperature for 15-20 min (the color of reaction mixture became intensively red) and then refluxed for 5 h. The formed precipitate was filtered, and the obtained solid was washed with CH₂Cl₂ and dried. In the case of homogenous solution, the solvent was evaporated to dryness, and the residue was purified by column chromatography (EtOAc-i-PrOH = 5:1), to give 6a-q as light yellow crystals.

2-(3- tert -Butyl-6-nitro-3 H -imidazo[4,5- b ]pyridin-5-yl)phenol (6a)
^¹H NMR (300 MHz, DMSO-d ₆): δ = 1.82 (s, 9 H, t-Bu), 6.87 (d, 1 H, H-6′, ^³ J = 9 Hz), 7.01 (t, 1 H, H-4′, ^³ J = 9 Hz), 7.30 (t, 1 H, H-5′, ^³ J = 9 Hz), 7.57 (d, 1 H, H-3′, ^³ J = 9 Hz), 8.71 (s, 1 H, H-5), 8.74 (s, 1 H, H-2), 9.95 (s, 1 H, OH). ^¹³C NMR (250 MHz, DMSO-d ₆): δ = 28.5 (CH₃), 57.7 [(CH₃)₃C], 115.1 (C-4′), 119.5 (C-6′), 123.6 (C-5′), 125.7 (C-3′), 130.2 (C-2′), 130.5 (C-1′), 133.9 (C-7), 142.8 (C-4), 144.7 (C-5), 147.1 (C-9), 148.2 (C-6), 154.5 (C-2). MS (EI): m/z (%) = 313 [M + 1]⁺(11), 312 [M]⁺(98), 210 [M - C₁₂H₉N₃O]⁺(77).

CCDC-782287 contain the crystallographic data (excluding structure factors) for the structures of 6g reported in this paper. This data have been deposited with the Cambridge Crystallographic Data Centre as supplementary material and can be obtained free of charge on application to CCDC,
12 Union Road, Cambridge CB2 1EZ, UK; fax:
+44 (1223)336033; e-mail: deposit@ccdc.cam.ac.uk or via www.ccdc.cam.ac.uk/data_request/cif.

<A NAME="RG12910ST-28A">28a</A> Dubois L, Evanno Y, Gille C, and Malanda A. inventors; WO 2009112677.

<A NAME="RG12910ST-28B">28b</A> Boyd E, Brookfield F, Gridley J, Honold K, Lau R, and Scheiblich S. inventors; WO 2007014707.

<A NAME="RG12910ST-28C">28c</A> Engh R, Hertenberger H, Honold K, Masjost B, Rueger P, Schaefer W, Scheiblich S, and Schwaiger M. inventors; WO 2007017143.

<A NAME="RG12910ST-28D">28d</A> Honold K, Kaluza K, Masjost B, Schaefer W, and Scheiblich S. inventors; WO 2006066914.

General Procedure for the Synthesis of Compounds 7a-q To a 100 mL Schlenk flask, filled with 200 mg of corresponding imidazo[4,5-b]pyridine 6a-q in MeOH (30 mL), Pd/C (20 mg, 10 mol%) was added. The flask was fitted with a septum, and then held under vacuum for 3 min, after that it was filled with hydrogen. Holding under vacuum was repeated one more time, and after sequent filling with hydrogen, the reaction mixture has been stirred for 2 d under H₂ atmosphere. After the reaction was stopped, the mixture was filtered through Celite pad and filtrate was evaporated to dryness or (if necessary) was purified by column chroma-tography (EtOAc-i-PrOH = 5:1) to give 7a-q as light brown crystals.

2-(3- tert -Butyl-6-amino-3 H -imidazo[4,5- b ]pyridin-5-yl)phenol (7a) ^¹H NMR (300 MHz, DMSO-d ₆): δ = 1.75 (s, 9 H, t-Bu), 4.86 (s, 2 H, NH₂), 6.97 (t, 1 H, H-4′, ^³ J = 9 Hz), 6.98 (d, 1 H, H-6′, ^³ J = 9 Hz), 7.28 (t, 1 H, H-5′, ^³ J = 9 Hz), 7.47 (d, 1 H, H-3′, ^³ J = 9 Hz), 7.48 (s, 1 H, H-5), 8,25 (s, 1 H, H-2), 10.27 (s, 1 H, OH). ^¹³C NMR (250 MHz, DMSO-d ₆): δ = 28.6 (CH₃), 56.1 [(CH₃)₃C], 113.5 (C-4′), 116.7 (C-6′), 119.4 (C-5′), 127.2 (C-3′), 129.1 (C-2′), 131.7 (C-1′), 136.2 (C-9), 137.5 (C-5), 140.2 (C-6), 141.0 (C-7), 142.6 (C-4), 154.6 (C-2). MS (EI): m/z (%) = 282 [M]⁺(71), 225 [M - C₁₂H₉N₄O]⁺(100).